Full Breakdown
High Court Allows PATHWAYS Puberty-Blockers Trial to Proceed
8/1/2026, 12:37:06 AM
Core Event
On 31 July 2026, Mr Justice Chamberlain dismissed a judicial-review challenge to the PATHWAYS clinical trial, clearing the way for the study to begin recruiting children. The judge concluded that none of the claimants’ grounds had a realistic prospect of success, allowing the trial to move forward as planned.
Background & Context
The PATHWAYS trial was commissioned after the April 2024 Cass Review, led by Baroness Cass, highlighted a “remarkably weak” evidence base for puberty-suppressing hormones in gender-incongruent youth. The review called for robust data to inform clinicians, families, and policy makers. In response, King’s College London (KCL) and South London and Maudsley NHS Foundation Trust designed the PATHWAYS study to fill that gap, seeking approval from the UK’s Health Research Authority (HRA) and the Medicines and Healthcare products Regulatory Agency (MHRA).
Data & Statistics
- Target enrollment: about 220 children aged 11-16 years.
- Eligibility: trans boys 11 and older; trans girls 12 and older.
- Study design: half of the participants will receive puberty-suppressing medication immediately, the other half will begin treatment a year later, creating a controlled comparison of outcomes.
- The trial focuses on children with persistent gender incongruence who are already receiving specialist NHS gender-service support.
Official Statements & Responses
Mr Justice Chamberlain emphasized that each prospective participant would have been assessed over “many months” by specialist doctors who formed the opinion that the child had a reasonable prospect of clinical benefit. He also noted that the trial had been designed with “conspicuous care” and had undergone rigorous scrutiny by the HRA and MHRA, which the court found to have acted lawfully and rationally.
The judgment further highlighted the public interest and the interests of trial participants as strong reasons to allow the research to continue.
Criticism & Opposition
The legal challenge was led by the Bayswater Support Group, a network that assists parents of gender-questioning children. The group argued that the PATHWAYS trial does not meet the legal and ethical thresholds required for research on minors, citing concerns about the study’s design, scale, and the limited prior evidence of benefit.
Psychotherapist James Esses and former trial participant Keira Bell, who detransitioned after earlier use of puberty blockers, expressed disappointment, describing the ruling as a “tragedy” and warning that medical practice and morality do not always align. Both critics maintain that the safeguards in place are insufficient to protect children from potential long-term physical and psychological harms.
What’s Next
Recruitment for the PATHWAYS trial is scheduled to begin on 1 August 2026. The study will continue under the oversight of the HRA, MHRA, and specialist clinical teams, with ongoing monitoring of safety and efficacy outcomes. Results are intended to inform future NHS gender-service protocols and address the evidence gap identified by the Cass Review.
